Beleggen.nl Markt MonitorMarkt Monitor

Amerikaanse aandelen Terug naar discussie overzicht

POET Technologies Inc.

3.208 Posts
Pagina: «« 1 ... 147 148 149 150 151 ... 161 »» | Laatste | Omlaag ↓
  1. veer62 19 februari 2020 07:49
    quote:

    hosternokke schreef op 18 februari 2020 23:27:

    veer vandaag blij met GXS neem ik aan?
    pffffffff heb alles verkocht op 0,08 dik verlies natuurlijk.zit nu in Eros maar dar wil ook nog niet echt.
  2. veer62 19 februari 2020 10:01
    quote:

    doewap schreef op 19 februari 2020 09:30:

    [...]

    niet dan?
    rustig doewap,ga je weer in aandelen verdiepen zoals we je kennen?
  3. veer62 19 februari 2020 13:44
    quote:

    doewap schreef op 19 februari 2020 11:42:

    rustig? ik ben zeer kalm veer :) ik doelde op de mooie plus in POET gisteren.

    Want POET heb ik wel. Meer dan ooit zelfs.
    dus je heb nog alle vertrouwen in poet doewap?
  4. $emi 19 februari 2020 16:10
    POET Technologies Confirms Receipt of Scheduled Payment

    19 févr. 2020 08h00 HE | Source : POET Technologies Inc.
    SAN JOSE, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) -- POET Technologies Inc. (“POET” or the “Company”) (OTCQX: POETF; TSX Venture: PTK), the designer and developer of the POET Optical Interposer and Photonic Integrated Circuits (PICs) for the data center and tele-communication markets, today confirmed that it had received a scheduled payment from the Buyer of DenseLight.

    In connection with the sale of DenseLight, its Singapore-based subsidiary, POET confirmed that it had received the scheduled Tranche 2a payment of US$4.75 million, despite the recent business interruptions in China resulting from COVID-19. The Company has initiated the transfer of an additional 19% of DenseLight shares from escrow to the Buyer (bringing the total to 49%). It also confirmed that the 2b payment of US$8.25 million, which will transfer an additional 32% to the Buyer (for a total of 81%) is on track to be paid by the end of March 2020.

    In connection with his appointment as Lead Independent Director in November 2019, the Board of Directors granted Peter Charbonneau options to purchase 35,488 common shares of the Company. The options are exercisable for 10 years at a price of C$0.42, being the closing price of the Company’s common stock on Wednesday, February 5, 2020. 25% of the options will vest immediately, with the remaining options vesting quarterly through October 2020. All the options were granted subject to provisions of the Company’s stock option plan and are subject to the TSX Venture Exchange policies and applicable securities laws. For further details on the Company’s share capital, refer to the Company’s Financial Statements and MD&A for the period ended September 30, 2019, which were filed on SEDAR on November 21, 2019.

    Additionally, POET announced the planned opening of an office and lab in Allentown, Pennsylvania on April 1, 2020. Concurrently, the Company has taken the required actions to close its office in San Jose, California.

    POET Technologies will be hosting analysts and strategic partners in conjunction with the Optical Fiber Communications (OFC) Conference & Exhibition on March 8 – 12 in San Diego, California.

    www.globenewswire.com/fr/news-release...
  5. [verwijderd] 19 februari 2020 16:26
    quote:

    veer62 schreef op 19 februari 2020 13:44:

    [...] dus je heb nog alle vertrouwen in poet doewap?
    Alle vertrouwen is wel veel veer. Maar ik geloof in Venkatesan, ja.
  6. [verwijderd] 19 februari 2020 16:34
    Allentown... daar hebben Cisco, Macom, Infinera en VLC photonics ook vestigingen. Dus daar kun je zaken doen en er is genoeg talent in de buurt.
  7. veer62 19 februari 2020 16:44
    quote:

    doewap schreef op 19 februari 2020 16:34:

    Allentown... daar hebben Cisco, Macom, Infinera en VLC photonics ook vestigingen. Dus daar kun je zaken doen en er is genoeg talent in de buurt.
    doewap is gelukkig weer terug top man.
  8. veer62 19 februari 2020 20:27
    quote:

    doewap schreef op 19 februari 2020 18:17:

    Ik zei al, veel gevonden maar slechte timing.

    Ik had ooit Enphase... jaren te vroeg. Kijk er maar eens naar.
    tjee pffffff en had je ze onder de 2dollar,ja man ik had cenx toen 2,50 dollar een jaar of wat later 25+.wnc voor een dollar later dik 23 dollar+ ik had steenrijk geweest als ik alles gehouden had, maar goed de haan heb nog niet gekraaid. Alhoewel ik nog heeeeeeeeeeel veel verlies heb.
  9. [verwijderd] 20 februari 2020 09:38
    Ik las een artikel op Simply Wall Street.

    Ik heb ze een mailtje gestuurd.

    Dear Editiorial team

    I track news on a company called POET Technologies. It popped up on your site, which I have also followed in recent years and thought of as a decent new development.

    But you do sometimes seem to pay lip service to the shorts. Take this new article:
    simplywall.st/news/poet-technologies-...

    It is hopelessly outdated. Not only is the market cap some 50% higher than stated, the company also retired most (if not all) of it's debt and has a good cash position at the moment. All of this is very much according to previously stated plans, which you would only have known had you actually followed the company. And yes, I understand that you just interpret data.

    The question is on your timing. Why do you publish data from September 2019, as fresh facts in February 2020?

    See here from november, a very much officially registered news release from the company:
    www.globenewswire.com/news-release/20...

    So it used the proceeds to retire it's debt and short term liabilities. Long term liabilities are virtually non existent, as you stated yourself in your article. As I see it, the company is debt free. Very much in a different risk class then, to your own definitions.

    The operational cost structure for the company is very much changed as well, after this divestment. And may I add, POET bought the place and made capex investments and hired 100% more staff, to develop it's new product. And then it sold the place for an amount that basically covered all of that cost.

    I understand you need reported numbers from the company, but you could elect not to publish data if in fact it is not current? The job really can be done better, with less of an obvious agenda.
3.208 Posts
Pagina: «« 1 ... 147 148 149 150 151 ... 161 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beleggen.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.097
AB InBev 2 5.525
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.862
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.770
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 192
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.764
Aedifica 3 923
Aegon 3.258 322.957
AFC Ajax 538 7.088
Affimed NV 2 6.297
ageas 5.844 109.896
Agfa-Gevaert 14 2.051
Ahold 3.538 74.343
Air France - KLM 1.025 35.219
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.046
Alfen 16 25.012
Allfunds Group 4 1.510
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 406
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.826
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.502
AMG 971 134.000
AMS 3 73
Amsterdam Commodities 305 6.734
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 491
Antonov 22.632 153.605
Aperam 92 15.027
Apollo Alternative Assets 1 17
Apple 5 384
Arcadis 252 8.787
Arcelor Mittal 2.034 320.848
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.332
Aroundtown SA 1 220
Arrowhead Research 5 9.747
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.443
ASML 1.766 108.719
ASR Nederland 21 4.502
ATAI Life Sciences 1 7
Atenor Group 1 521
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.690
Axsome Therapeutics 1 177
Azelis Group 1 66
Azerion 7 3.410